Clovis Oncology’s Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults

 Clovis Oncology’s Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults

Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Shots:

  • The approval is based on P-III ARIEL3 study results assessing Rubraca (600mg, bid) vs PBO in 564 women in a ratio (2:1) with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to PT-based CT
  • P-III ARIEL3 study results: PFS events (62% vs 88%); mPFS (10.8mos. vs 5.4mos.); In tBRCA Group: PFS events (52% vs 85%); mPFS (16.6mos. vs 5.4mos.), CR 7%; Tumor response (18% vs 8%)
  • Rubraca (rucaparib) is an inhibitor of PARP1, PARP2 and PARP3 targeted as a monothx or in combination for multiple tumor types, including ovarian, metastatic castration-resistant prostate and bladder cancers

Click here to read full press release/ article | Ref:ClovisOncology | Image: Innovation News

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post